Sight Sciences, Inc. announced it has launched the Ergo-Series for its OMNI Surgical System in the United States—designed to be used for patients with primary open-angle glaucoma (POAG) during minimally-invasive glaucoma surgery (MIGS) as well as before, in combination with, or after cataract surgery.
Tell me more about OMNI.
Cleared by the FDA in 2021, the OMNI Surgical System is the first and currently only implant-free, single-use therapeutic glaucoma device indicated for canaloplasty followed by trabeculotomy in order to reduce intraocular pressure (IOP).
It works by opening and potentially restoring flow through the three points of known resistance within the conventional outflow pathway (trabecular meshwork, Schlemm’s canal, and collector channels) of the eye via a single, clear corneal microincision.
Now talk about the Ergo-Series.
This new design builds on the original system by incorporating three new features:
- Improved ergonomic function for easier rotation and positioning of the cannula tip within Schlemm’s canal
- Removable and detachable viscoelastic luer connector during removal of viscoelastic cartridge
- Cannula-tip profile with more gentle and precise access to Schlemm’s canal (while maintaining typical 360-degree catheterization of the OMNI system)
Where is it launching?
According to Sight Sciences, the Ergo-Series is launching across the United States. The company expects it to be made available outside the U.S. later in 2023.